Atripla (Physicians Total Care, Inc.)
Welcome to the PulseAid listing for the Atripla drug offered from Physicians Total Care, Inc.. This Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [Chemical/Ingredient],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Cytochrome P450 3A Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA],Cytochrome P450 2C9 Inhibitors [MoA],Cytochrome P450 2C19 Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Physicians Total Care, Inc. |
| NON-PROPRIETARY NAME: | efavirenz, emtricitabine, and tenofovir disoproxil fumarate |
| SUBSTANCE NAME: | EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [Chemical/Ingredient],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Cytochrome P450 3A Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA],Cytochrome P450 2C9 Inhibitors [MoA],Cytochrome P450 2C19 Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2012-10-16 |
| END MARKETING DATE: | 0000-00-00 |
Atripla HUMAN PRESCRIPTION DRUG Details:
| Item Description | Atripla from Physicians Total Care, Inc. |
| LABELER NAME: | Physicians Total Care, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 600; 200; 300(mg/1; mg/1; mg/1) |
| START MARKETING DATE: | 2012-10-16 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 54868-5643_969b3a71-6ed6-4604-a2aa-ab8fe3624bcb |
| PRODUCT NDC: | 54868-5643 |
| APPLICATION NUMBER: | NDA021937 |
Other EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Pharmaceutical Manufacturers / Labelers:
